Danielle Elyse Antin-Ozerkis MD
Critical Care Medicine
Associate Professor, Internal Medicine, Yale University School of Medicine
Join to View Full Profile
6 Devine StreetYale New Haven Health North Haven Medical CenterNorth Haven, CT 06473
Dr. Antin-Ozerkis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Pennsylvania Health SystemFellowship, Pulmonary Disease and Critical Care Medicine, 2002 - 2006- University of Pennsylvania Health SystemResidency, Internal Medicine, 1999 - 2002
Perelman School of Medicine at the University of PennsylvaniaClass of 1999
Certifications & Licensure
CT State Medical License 2006 - 2026
PA State Medical License 2000 - 2006
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
Clinical Trials
- Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF Start of enrollment: 2009 Oct 01
- AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis Start of enrollment: 2009 Oct 01
- Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
Publications & Presentations
PubMed
- 4 citationsContinued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ON.Wim A Wuyts, Francesco Bonella, Nazia Chaudhuri, Francesco Varone, Danielle Antin-Ozerkis
Lung. 2025-01-09 - 6 citationsToll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis.Glenda Trujillo, Alicia Regueiro-Ren, Chunjian Liu, Buqu Hu, Ying Sun
American Journal of Respiratory and Critical Care Medicine. 2025-01-01 - 81 citations2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in Peo...Sindhu R Johnson, Elana J Bernstein, Marcy B Bolster, Jonathan H Chung, Sonye K Danoff
Arthritis & Rheumatology. 2024-08-01
Press Mentions
Yale Faculty Contribute to National Interstitial Lung Disease GuidelineJanuary 28th, 2025- Pulmonary, Critical Care and Sleep MedicineSeptember 23rd, 2024
- 2023 ‘Top Doctors’ List Features Over 250 Yale Medicine PhysiciansMay 3rd, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
